Grace Therapeutics (GRCE) Change in Receivables (2019 - 2025)
Grace Therapeutics (GRCE) posted Change in Receivables of -$106000.0 for Q2 2025, up 39.43% sequentially from -$175000.0 in Q1 2025, and up 67.48% YoY from -$63289.4 in Q2 2024.
Grace Therapeutics (GRCE) Change in Receivables (2019 - 2025) Analysis & Trends
Grace Therapeutics has reported Change in Receivables for 6 years, with the latest figure at -$106000.0 in Q2 2025.
- Quarterly Change in Receivables rose 67.48% year-over-year to -$106000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$106000.0 (up 82.21% YoY) and the FY2026 annual result came in at -$106000.0, up 82.21% from the prior year.
- Change in Receivables climbed to -$106000.0 in Q2 2025 per GRCE's latest filing, from -$175000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $380000.0 in Q3 2021 and troughed at -$326000.0 in Q2 2024.
- A 4-year average of -$35250.0 and a median of -$37000.0 in 2021 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2021 and 2024: Change in Receivables surged 219.33% in 2021, then slumped 1031.43% in 2024.
- Over 4 years, Change in Receivables stood at $380000.0 in 2021, then plunged by 67.89% to $122000.0 in 2023, then plunged by 193.44% to -$114000.0 in 2024, then rose by 7.02% to -$106000.0 in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered -$106000.0, -$175000.0, and -$114000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Grace Therapeutics | 38.17 Mn | 38.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -106,000.00 |
| Jun 30, 2025 | -106,000.00 |
| Mar 31, 2025 | -175,000.00 |
| Mar 31, 2025 | -175,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | -326,000.00 |
| Jun 30, 2024 | -326,000.00 |
| Mar 31, 2024 | -237,000.00 |
| Mar 31, 2024 | -237,000.00 |
| Dec 31, 2023 | 122,000.00 |
| Dec 31, 2023 | 122,000.00 |
| Jun 30, 2023 | 35,000.00 |
| Jun 30, 2023 | 35,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Sep 30, 2021 | 380,000.00 |
| Sep 30, 2021 | 380,000.00 |